What to expect on cost.

We publish cost ranges because families deserve to set expectations honestly before they start a conversation with us, not at the end. The numbers below are indicative bands by therapy modality; they reflect what a single course of treatment, coordinated through our pipeline into one of the countries we serve, has typically cost recent families. They are neither list prices nor insurance-adjusted prices, and they are not a quote. A quote is patient-specific, written, and issued only after we have reviewed the prescription, the destination, the required pack size, and the logistics profile of the case. What follows is the envelope inside which most quotes land.

What is inside these ranges

Every range on this page bundles four components: the manufacturer's cost basis for the specific product and pack configuration, the documented import duty and freight to the destination country, the cold-chain logistics cost for the therapy's temperature profile, and our coordination fee. We break those line items out explicitly in every quote we issue, because an opaque bundled price is the single most common complaint families bring to us about previous providers. If you are comparing a Reserve Meds quote against another coordinator's figure, ask the other coordinator to do the same breakdown; that is usually where the real differences show up.

Oncology, specialty and rare indications

A single course of specialty or rare-indication oncology therapy, coordinated and delivered to a patient in one of our destination countries, typically falls between roughly twenty-five thousand and three hundred fifty thousand US dollars. The low end of that range covers short courses of newer targeted oral agents where the pack size is modest and the cold-chain profile is straightforward. The upper end covers longer-cycle biologics and combination regimens where multiple cycles, refrigerated shipping, and more extensive customs documentation all stack into the final figure. Most oncology cases we have seen in the last twelve months have landed in the middle of that band, between sixty thousand and one hundred eighty thousand US dollars for a typical course as defined by the prescriber.

Rare-disease biologics

For rare-disease biologics outside oncology, including enzyme replacement therapies, complement inhibitors, and specialty immunology agents, the indicative range sits between roughly forty thousand and five hundred thousand US dollars, and occasionally higher. This category has unusually high dispersion because pack sizes, dosing frequency, and patient weight all drive annual cost significantly, and because the duration of therapy is often measured in years rather than cycles. Families entering this category benefit from discussing the first-year budget and the steady-state annual cost separately with us; we will quote both if the prescriber's treatment plan supports that framing.

Gene and cell therapies

Gene and cell therapies sit in a band of their own. A single administration of an approved gene therapy, or a single CAR-T or equivalent autologous cell product, typically falls between roughly four hundred thousand and three and a half million US dollars, and one-administration gene therapies in the highest-cost range can exceed that ceiling. The cost basis here is dominated by the manufacturer price of the one-time product; logistics and coordination matter materially but are a smaller share of the total than in the other categories. Families considering a gene- or cell-therapy pathway should expect the quote process to take longer than a conventional specialty case, because the logistics profile for ultra-cold and LN2 shipping requires validated capacity at both ends and a confirmed apheresis or infusion slot at the receiving institution.

What these ranges are not

These are not list prices; list prices are published by manufacturers and by drug-pricing indices, and they do not reflect the real landed-in-destination cost for a cross-border patient. They are not insurance-adjusted; Reserve Meds is cash-pay only, we do not bill insurance, and we do not reflect payer concessions in our figures. They are not a quote; a quote is issued in writing, tied to a specific prescription and destination, and held open for a defined window. Finally, they are not a guarantee that we can source at the low end of a range for any given case; sourcing, duty, and logistics vary by product and by date, and a case-specific quote is the only number a family should make a decision on.

Our coordination fee, transparently

Our coordination fee is disclosed up front and quoted as a separate, stated figure on every case. It is not a percentage of drug cost, it is not a volume-tiered rebate, and it does not vary based on the prescriber making the referral. The fee covers the work of the case: intake review by our AI Clinical Review Agent and AI Regulatory Review Agent, human pharmacist review of the prescription, documentation preparation for the destination country's named-patient pathway, coordination with our US specialty wholesaler and with Altima Care as the dispensing pharmacy, cold-chain logistics management, and ongoing case coordination through delivery and the first follow-up cycle. For more on how we think about pricing structurally, see how we think about pricing.

The honest caveat

Published ranges age. Manufacturer pricing moves, duty regimes change, and freight economics shift with fuel and with regional logistics capacity. We reissue these bands on a quarterly cadence and carry the review date in the footer of this page. If you are reading this page more than three months after the review date shown, treat the ranges as a rough orientation and reach out for a current quote before making any financial plan.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.